NCT06054152Completed
CX3CR1+T Cell Predict Immunotherapy Efficacy
Prediction of Immunotherapy Efficacy Based on Transcriptome of CX3CR1+T Cell in Peripheral Blood
Source: ClinicalTrials.gov · Last updated 25 Jun 2025
Brief summary (registry, in English)
This study aimed to evaluate the correlation between the proportion of flow-sorted CX3CR1+T cells in peripheral blood and the CX3CR1+T-specific gene signature and the efficacy of immunotherapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 19 Sept 2023
- Start date
- 10 Apr 2023
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Lung cancer
- NCT number
- NCT06054152
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 10 Apr 2023 to the primary completion date, 1 Jan 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any history of antitumor therapy;
- Patients with a history of other systemic tumors;
Lab values
- Genetic test showed EGFR and ALK mutations;
Other
- Patients with other co-morbidities that may affect their follow-up and short-term survival;
- The ineligible participants assessed by the researchers
Who the study is looking for
- At least 18 years old;
- Diagnosed as Non-small cell lung cancer by biopsy before treatment;
- Prepare to receive PD(L)1 inhibitor monotherapy or combined chemotherapy and antivascular drugs;
- Lesion imaging can be measured and evaluated by RECIST1.1 standard;
- Life expectancy exceeds 3 months;
- ECOG score 0-2;
- The newly IO treated patients did not receive immunotherapy, chemoradiotherapy before participate in the trial;
- Sign informed consent and be willing to provide 5ml of peripheral blood for research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hunan Cancer Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.